Add-On Olaparib Continues to Show Benefit in First-Line Treatment of mCRPC

(MedPage Today) -- SAN FRANCISCO -- Adding the PARP inhibitor olaparib (Lynparza) to standard-of-care abiraterone (Zytiga) as initial treatment for metastatic castration-resistant prostate cancer (mCRPC) extended median progression-free survival...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news